has joined the OLIGOFASTX project that seeks to develop a comprehensive, transversal and sustainable platform for new therapies based on RNA oligonucleotides (ASOs, siRNAs and aptamers), which promotes and facilitates the arrival on the market of new innovative therapies for the treatment of rare diseases in Spain. Aptus will make use of their mnk1b aptamer, Q2, to develop a novel approach in the treatment of anaplastic thyroid carcinoma. The OLIGOFASTX project is led by Sylentis, S.A. (Pharma Mar Group) and brings together 7 Spanish companies: Sylentis, Nanovex, BDI Biotech, Nostrum Biodiscovery, Arthex Biotech, AptaTargets and AptusBiotech Visit https://aptusbiotech.com/oligofastx/ for more information